161 related articles for article (PubMed ID: 19583808)
1. Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin.
Suzuki A; Horiuchi A; Ashida T; Miyamoto T; Kashima H; Nikaido T; Konishi I; Shiozawa T
J Cell Mol Med; 2010 Sep; 14(9):2305-17. PubMed ID: 19583808
[TBL] [Abstract][Full Text] [Related]
2. LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1.
Chen C; Wang Y; Wang S; Liu Y; Zhang J; Xu Y; Zhang Z; Bao W; Wu S
Int J Oncol; 2017 Mar; 50(3):942-952. PubMed ID: 28098854
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
4. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
[TBL] [Abstract][Full Text] [Related]
5. Lipocalin 2 Enhances Migration and Resistance against Cisplatin in Endometrial Carcinoma Cells.
Miyamoto T; Kashima H; Yamada Y; Kobara H; Asaka R; Ando H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
PLoS One; 2016; 11(5):e0155220. PubMed ID: 27168162
[TBL] [Abstract][Full Text] [Related]
6. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
8. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
[TBL] [Abstract][Full Text] [Related]
10. Bag-1 silencing enhanced chemotherapeutic drug-induced apoptosis in MCF-7 breast cancer cells affecting PI3K/Akt/mTOR and MAPK signaling pathways.
Kilbas PO; Akcay IM; Doganay GD; Arisan ED
Mol Biol Rep; 2019 Feb; 46(1):847-860. PubMed ID: 30661182
[TBL] [Abstract][Full Text] [Related]
11. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
12. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Wang Y; Gao C; Zhang Y; Gao J; Teng F; Tian W; Yang W; Yan Y; Xue F
Gynecol Oncol; 2016 Oct; 143(1):168-178. PubMed ID: 27473926
[TBL] [Abstract][Full Text] [Related]
13. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
14. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation.
Catalano S; Giordano C; Rizza P; Gu G; Barone I; Bonofiglio D; Giordano F; Malivindi R; Gaccione D; Lanzino M; De Amicis F; Andò S
J Cell Physiol; 2009 Mar; 218(3):490-500. PubMed ID: 18988190
[TBL] [Abstract][Full Text] [Related]
15. miR‑494‑3p promotes the progression of endometrial cancer by regulating the PTEN/PI3K/AKT pathway.
Zhu L; Wang X; Wang T; Zhu W; Zhou X
Mol Med Rep; 2019 Jan; 19(1):581-588. PubMed ID: 30431102
[TBL] [Abstract][Full Text] [Related]
16. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9.
Van Themsche C; Mathieu I; Parent S; Asselin E
J Biol Chem; 2007 Feb; 282(7):4794-4802. PubMed ID: 17150964
[TBL] [Abstract][Full Text] [Related]
18. The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer.
Chitcholtan K; Sykes PH; Evans JJ
J Transl Med; 2012 Mar; 10():38. PubMed ID: 22394685
[TBL] [Abstract][Full Text] [Related]
19. Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.
Dong L; Du M; Lv Q
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):753-760. PubMed ID: 31168597
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
